MPLT — MapLight Therapeutics, Inc. catalysts
Next verified catalyst
2026-08-01 — A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adu · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-08 (month) in 1mo
ESTIMATED |
READOUT
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inp
Phase 2 · Schizophrenia |
MPLT MapLight Therapeutics, Inc. | ML-007C-MA BID, ML-007C-MA QD |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|